Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Company Summary - Panlong Qiniang Gel Patch is developed from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of convenience, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis with symptoms of Qi stagnation and blood stasis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [1] Company Summary - Panlong Qining Gel Patch is an improved formulation derived from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of ease of use, speed of effect, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [1] Company Summary - Panlong Qining Gel Patch is an improved formulation derived from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of ease of use, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Core Viewpoint - The company, Panlong Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Company Summary - Panlong Qiniang Gel Patch is developed from Panlong Qiyao Wine, consisting of 30 medicinal ingredients including Panlong Qiyao and Zhuangjindan [1] - The new gel patch formulation offers significant advantages over the original form in terms of convenience, speed of action, and target user demographics [1] - The primary therapeutic functions of the product include promoting blood circulation, dispelling wind and dampness, and reducing swelling and pain, specifically for knee osteoarthritis with symptoms of Qi stagnation and blood stasis [1]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-051 陕西盘龙药业集团股份有限公司 申请事项：药物临床试验 受理号：CXZL2500066 申请人：陕西盘龙药业集团股份有限公司 审批结论：同意本品开展用于膝骨关节炎的临床试验 二、药品的其他相关情况 关于公司获得药物临床试验批准通知书的自愿性信息披露 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，陕西盘龙药业集团股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，同意盘龙七凝胶贴膏开展 用于膝骨关节炎的临床试验。现将有关情况公告如下： 一、药品相关情况 产品名称：盘龙七凝胶贴膏 盘龙七凝胶贴膏是由盘龙七药酒（国药准字 Z61021120）改良而来，处方由 盘龙七、壮筋丹等 30 味药材组成，开发成凝胶贴膏剂，该产品较原剂型在使用 便捷性、起效速度、使用人群等方面均有明显优势，其主治功能为活血化瘀、祛 风除湿、消肿止痛。适用于膝骨关节炎（气滞血瘀证）。 三、对公司的影响及风险提示 如公司临床试验申请进展顺利，将有利于公司拓宽业务范围、优化产 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its Panlong Qiniang Gel Patch for knee osteoarthritis [1] Group 1: Product Development - The Panlong Qiniang Gel Patch is derived from the improved Panlong Qijiu and consists of a formula made from 30 medicinal ingredients including Panlong QI and Zhuangjindan [1] - The primary functions of the product are to invigorate blood circulation, dispel wind and dampness, and reduce swelling and pain, specifically targeting knee osteoarthritis characterized by Qi stagnation and blood stasis [1]

Group 1 - The outbreak of respiratory syncytial virus (RSV) in Tianjin has peaked earlier than expected, with flu activity rising in southern provinces and most northern provinces during the 44th week of 2025 [1] - The latest flu monitoring report from the National Disease Control indicates an increase in flu cases, highlighting the need for vigilance against RSV alongside influenza [4] Group 2 - In the A-share market, flu-related stocks are experiencing significant activity, with Aipeng Medical rising over 10%, and other companies like Panlong Pharmaceutical hitting the daily limit, indicating strong investor interest [2] - The detection rates for severe acute respiratory infections show that rhinovirus (10.6%), RSV (8.5%), and influenza virus (4.2%) are the top three pathogens, emphasizing the impact of RSV on public health [4]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Group 1 - The innovative drug concept is experiencing a significant upward trend, with companies like Panlong Pharmaceutical reaching the daily limit increase [1] - Other companies showing notable gains include Jinhua Co., Enwei Pharmaceutical, Tonghua Jinma, SanSheng Guojian, and Rejing Biological [1]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]